1. Show article details.

    Health care stocks take a broad beating as sector turns negative on the year

    MarketWatch – 1:12 PM ET 10/06/2015

    Health care stocks are taking a broad beating in afternoon trade Tuesday, as investor sentiment toward the once hot sector continues to sour in the face of public outrage over surge pricing of certain drugs. The SPDR Health Care ETF dropped 3%, with all 55 of its equity components trading trading lower. Only three of the 55 stocks declined less than 1%.

  2. Show article details.

    Abbott Celebrates Living Fully Through the Power of Health as an Official Sponsor of the 2015 Bank of America Chicago Marathon

    PR Newswire – 1:00 PM ET 10/01/2015

    ABBOTT PARK, Ill., Oct. 1, 2015 In its second year as an Official Sponsor of the Bank of America Chicago Marathon, Abbott will again demonstrate its commitment to helping people achieve their goals through good health.

  3. Show article details.

    Abbott Hosts Conference Call for Third-Quarter Earnings

    PR Newswire – 9:00 AM ET 09/30/2015

    ABBOTT PARK, Ill., Sept. 30, 2015  Abbott will announce its third-quarter 2015 financial results on Wednesday, Oct. 21, 2015, before the market opens.

  4. Show article details.

    Sponsorships and Partnerships for Scheduled Events - Report on Abbott Laboratories

    PR Newswire – 9:15 AM ET 09/23/2015

    NEW YORK, September 23, 2015 ACI Association has initiated research coverage on Abbott Laboratories (ABT). Select highlights from the internally released reports are being made available to the general public, with access to the entirety of the research available to new members.

  5. Show article details.

    What Does It Mean to Live Fully?

    PR Newswire – 10:00 AM ET 09/22/2015

    ABBOTT PARK, Ill., Sept. 22, 2015  What does it look like to really live a full life – one that enriches and satisfies, that provides happiness and enables achievement?

  6. Show article details.

    Abbott Marks 15 Years of Helping Career-Minded Moms Reach Their Full Professional Potential

    PR Newswire – 8:00 AM ET 09/22/2015

    ABBOTT PARK, Ill., Sept. 22, 2015  Abbott's commitment to support working mothers with progressive benefits and extraordinary career opportunities was recognized today by Working Mother magazine.

  7. Show article details.

    Mexican drug maker Rimsa seeks buyers -Bloomberg

    Reuters – 7:53 PM ET 09/18/2015

    Privately owned Mexican drug maker Representaciones e Investigaciones Medicas, or Rimsa, is up for sale and could be worth as much as $1 billion, Bloomberg reported on Friday, citing people familiar with the matter. Goldman Sachs is managing the sale of Rimsa, which has attracted interest from companies including Sanofi, Pfizer and Abbott Laboratories (ABT), the people told Bloomberg.

  8. Show article details.

    Medical Appliances and Equipment Stocks Technical Report -- Boston Scientific, Abbott Laboratories, Medtronic, Stryker, and Edwards Lifesciences

    PR Newswire – 8:30 AM ET 09/18/2015

    NEW YORK, September 18, 2015 Equity Research Institute has initiated coverage on the following equities: Boston Scientific Corporation (BSX), Abbott Laboratories (ABT), Medtronic PLC (MDT), Stryker Corporation (SYK), and Edwards Lifesciences Corporation.

  9. Show article details.

    Abbott Declares 367th Consecutive Quarterly Dividend

    PR Newswire – 9:00 AM ET 09/17/2015

    ABBOTT PARK, Ill., Sept. 17, 2015  The board of directors of Abbott today declared a quarterly common dividend of 24 cents per share. This marks the 367th consecutive quarterly dividend to be paid by Abbott since 1924.

  10. Show article details.

    Abbott Named Industry Leader for Responsible and Sustainable Business for Three Consecutive Years on the Dow Jones Sustainability Index (DJSI)

    PR Newswire – 12:47 PM ET 09/10/2015

    ABBOTT PARK, Ill., Sept. 10, 2015 For the third consecutive year, Abbott has been named the leading company in its industry by the Dow Jones Sustainability Index, one of the most prestigious global benchmarks for corporate responsibility and sustainability.

  11. Show article details.

    Jean Boulle Group – US$250 Million+ Abbott Laboratories Acquisition of Tendyne Holdings Mitral Valve Company Confirms the Group’s Pedigree for Making Serial Major Discoveries from Mines to Medical technology.

    Business Wire – 7:00 PM ET 09/08/2015

    Jean Boulle Medtech Ltd, a Jean Boulle Group medical technology company and founding investor of Tendyne Holdings, Inc., is pleased to announce that Abbott Laboratories (ABT) has closed its acquisition of Tendyne.

  12. Show article details.

    Abbott Completes Acquisition of Tendyne Holdings, Inc.

    PR Newswire – 9:00 AM ET 09/02/2015

    ABBOTT PARK, Ill., Sept. 2, 2015  Abbott announced today that it has completed its acquisition of Tendyne Holdings, Inc., a private medical device company focused on developing minimally invasive mitral valve replacement therapies.

  13. Show article details.

    Abbott Announces Positive Results of Its Naturally Dissolving Stent from ABSORB Japan Study

    PR Newswire – 4:00 AM ET 09/01/2015

    LONDON, Sept. 1, 2015  Abbott announced today positive one-year clinical results from ABSORB Japan, a multi-center, randomized trial comparing the safety and effectiveness of Abbott's fully dissolving Absorb™ heart stent to XIENCE ®, Abbott's market-leading, permanent drug eluting stent.

  14. Show article details.

    Drugmaker Abbott says not pursuing an offer for St Jude Medical

    Reuters – 10:21 AM ET 08/27/2015

    - Drugmaker Abbott Laboratories , knocking down a report in the Financial Times, denied on Thursday that it was preparing a bid for medical device maker St Jude Medical Inc (STJ) . The FT, citing people familiar with the matter, reported that Abbott has been working with advisers for several weeks to line up financing for a $25 billion cash and stock bid for St. Paul, Minnesota-based St...

  15. Abbott Laboratories up 3% as it denies St. Jude acquisition talk

    MarketWatch – 9:38 AM ET 08/27/2015
  16. Show article details.

    Abbott says it's not pursuing $25 billion offer for St. Jude

    MarketWatch – 8:49 AM ET 08/27/2015

    Abbott Laboratories (ABT) has denied reports that it is pursuing a $25 billion bid to buy St. Jude traded sharply higher in premarket trade following a Financial Times report, citing anonymous sources. Jude's shares were up 5% in premarket trade, putting them on track to open around $73. Those of Abbott were up 3.2%.

  17. Abbott says it's not pursuing an offer for St. Jude

    MarketWatch – 8:40 AM ET 08/27/2015
  18. Abbott Labs' stock rallies 3.5% premarket after report of takeover interest in St. Jude Medical

    MarketWatch – 7:49 AM ET 08/27/2015
  19. Abbott Labs preparing $25 bln bid for St. Jude Medical: FT

    MarketWatch – 7:23 AM ET 08/27/2015
  20. Show article details.

    St. Jude Medical shares surge 13% on report Abbott Labs prepping $25 bln bid

    MarketWatch – 7:21 AM ET 08/27/2015

    Jude Medical Inc. shares surged 12% in premarket trade Thursday, after the Financial Times reported that Abbott Laboratories (ABT) is gearing up to make a $25 billion bid for the medical device maker, citing people familiar with the matter. The company is preparing an offer but has not yet put it forward, the paper said. Abbott Labs (ABT) shares were not yet active in premarket trading.


Today's and Upcoming Events

  • Oct

    ABT ex-Dividend for $0.24 on 10/13/2015

    • Announce Date: 9/17/2015
    • Record Date: 10/15/2015
    • Pay Date: 11/15/2015
  • Oct

    ABT to announce Q3 earnings Before Market (Confirmed)

  • Oct

    ABT Earnings Conference Call at 9:00 AM Listen

Past Events (last 90 days)

No events in the past 90 days

Data provided by Wall Street Horizon, Inc. © 2015

Technical Events

Technical Analysis

As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.

Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.